A national multicentre randomized study comparing the early versus delayed administration of everolimus in de novo kidney transplant recipients at risk of delayed graft function.

Trial Profile

A national multicentre randomized study comparing the early versus delayed administration of everolimus in de novo kidney transplant recipients at risk of delayed graft function.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2011

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms CALLISTO
  • Sponsors Novartis
  • Most Recent Events

    • 30 Aug 2009 Tolerability results presented at the 14th Congress of the European Society for Organ Transplantation.
    • 30 Aug 2009 One-year results presented at the 14th Congress of the European Society for Organ Transplantation, 2009.
    • 27 Jul 2009 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top